New AI Platform Builds on a 30+ Country Physician Network and the ISSCA Mobile App to Create a Connected, Technology-Enabled Ecosystem for Regenerative and Longevity Medicine
MIAMI, FL / ACCESS Newswire / June 23, 2026 / Regenerative Medical Technologies Group, Inc. (the "Company" or "RMTG") (OTC PINK:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the launch of the ISSCA AI™ Clinical Intelligence Platform, a next-generation artificial intelligence system developed by its education and innovation division, the International Society for Stem Cell Application (ISSCA). The platform is designed to assist physicians in interpreting clinical data, organizing treatment workflows, and managing increasing data complexity - while preserving full clinical oversight. The Company believes ISSCA AI™ represents a significant step in its strategy to convert an established global physician network into a connected, technology-enabled clinical ecosystem.
From Education Leader to AI-Enabled Clinical Infrastructure
A Strategic Step Toward a Connected Clinical Ecosystem
For more than 15 years, ISSCA has built physician relationships, clinical protocols, and credibility across regenerative medicine in over 30 countries. With the recent launch of the ISSCA Mobile App and now the ISSCA AI™ Clinical Intelligence Platform, RMTG is methodically building the digital infrastructure layer on top of that network - moving from education and training into recurring, technology-enabled clinical services.
